期刊
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
卷 89, 期 1, 页码 78-88出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/jnnp-2017-316213
关键词
-
资金
- Michael J. Fox Foundation for Parkinson's Research (MJFF)
- MJFF
- Abbvie
- Avid Radiopharmaceuticals
- Biogen Idec
- Bristol-Myers Squibb
- Biolegend
- Eli Lilly Co.
- F. Hoffman-La Roche, Ltd.
- GE Healthcare
- Genentech
- GlaxoSmithKline
- Lundbeck
- Merck
- MesoScale
- Piramal
- Pfizer
- Servier
- TEVA
- Takeda
- Sanofi Genzyme
- UCB
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL091843] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS053488, U01NS079163, U01NS082329, U01NS077108, U01NS038529, U01NS084495, U01NS077352] Funding Source: NIH RePORTER
Objective To examine the baseline prevalence and longitudinal evolution in non-motor symptoms (NMS) in a prospective cohort of, at baseline, patients with de novo Parkinson's disease (PD) compared with healthy controls (HC). Methods Parkinson's Progression Markers Initiative (PPMI) is a longitudinal, ongoing, controlled study of de novo PD participants and HC. NMS were rated using the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I score and other validated NMS scales at baseline and after 2 years. Biological variables included cerebrospinal fluid (CSF) markers and dopamine transporter imaging. Results 423 PD subjects and 196 HC were enrolled and followed for 2 years. MDS-UPDRS Part I total mean (SD) scores increased from baseline 5.6 (4.1) to 7.7 (5.0) at year 2 in PD subjects (p<0.001) versus from 2.9 (3.0) to 3.2 (3.0) in HC (p=0.38), with a significant difference between the groups (p<0.001). In the multivariate analysis, higher baseline NMS score was associated with female sex (p=0.008), higher baseline MDS-UPDRS Part II scores (p<0.001) and more severe motor phenotype (p=0.007). Longitudinal increase in NMS severity was associated with the older age (0.008) and lower CSF A beta 1-42 (0.005) at baseline. There was no association with the dose or class of dopaminergic therapy. Conclusions This study of NMS in early PD identified clinical and biological variables associated with both baseline burden and predictors of progression. The association of a greater longitudinal increase in NMS with lower baseline A beta 1-42 level is an important finding that will have to be replicated in other cohorts.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据